Enhanced immune responses by skin vaccination with influenza subunit vaccine in young hosts

Vaccine

Volumn 33, Issue 37, 2015, Pages 4675-4682

  Koutsonanos, Dimitrios G ^a   Esser, E Stein ^a   McMaster, Sean R ^a   Kalluri, Priya ^b   Lee, Jeong Woo ^b   Prausnitz, Mark R ^b   Skountzou, Ioanna ^a   Denning, Timothy L ^c   Kohlmeier, Jacob E ^a   Compans, Richard W ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Georgia Institute of Technology   (United States)

^c GEORGIA STATE UNIVERSITY   (United States)

Author keywords

Influenza; Skin immunization; Vaccine

Indexed keywords

IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INFLUENZA VACCINE; SUBUNIT VACCINE; IMMUNOGLOBULIN G; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY SECRETING CELL; ANTIBODY TITER; ANTIGEN PRESENTING CELL; ARTICLE; BONE MARROW CELL; CELLULAR IMMUNITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GERMINAL CENTER; HELPER CELL; HUMORAL IMMUNITY; INFLUENZA; INFLUENZA VACCINATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; WEIGHT CHANGE; WEIGHT REDUCTION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; COMPARATIVE STUDY; DRUG DELIVERY SYSTEM; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); INTRADERMAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; LUNG; ORTHOMYXOVIRIDAE INFECTIONS; PROCEDURES; SURVIVAL ANALYSIS; T LYMPHOCYTE; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ANIMALS; ANTIBODIES, VIRAL; DRUG DELIVERY SYSTEMS; FEMALE; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAMUSCULAR; LUNG; MICE, INBRED BALB C; MODELS, ANIMAL; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TREATMENT OUTCOME; VACCINES, SUBUNIT; VIRAL LOAD;

EID: 84940450494     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.01.086     Document Type: Article

References (54)

1. Fiore A.E., Shay D.K., Broder K., Iskander J.K., Uyeki T.M., Mootrey G., et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 2008, 57:1-60.
2. Monto A.S. Seasonal influenza and vaccination coverage. Vaccine 2010, 28(Suppl. 4):D33-D44.
3. Foster D.A., Talsma A., Furumoto-Dawson A., Ohmit S.E., Margulies J.R., Arden N.H., et al. Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly. Am J Epidemiol 1992, 136:296-307.
4. Baldo V., Baldovin T., Pellegrini M., Angiolelli G., Majori S., Floreani A., et al. Immunogenicity of three different influenza vaccines against homologous and heterologous strains in nursing home elderly residents. Clin Dev Immunol 2010, 2010:517198.
5. Glathe H., Bigl S., Grosche A. Comparison of humoral immune responses to trivalent influenza split vaccine in young, middle-aged and elderly people. Vaccine 1993, 11:702-705.
6. Anar C., Bicmen C., Yapicioglu S., Unsal I., Halilcolar H., Yilmaz U. Evaluation of clinical data and antibody response following influenza vaccination in patients with chronic obstructive pulmonary disease. New Microbiol 2010, 33:117-127.
7. Bickel M., Wieters I., Khaykin P., Nisius G., Haberl A., Stephan C., et al. Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. AIDS 2010, 24:F31-F35.
8. Nolan T., McVernon J., Skeljo M., Richmond P., Wadia U., Lambert S., et al. Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. JAMA 2010, 303:37-46.
9. Schmidt-Ott R., Schwarz T., Haase R., Sander H., Walther U., Fourneau M., et al. Immunogenicity and reactogenicity of a trivalent influenza split vaccine in previously unvaccinated children aged 6-9 and 10-13 years. Vaccine 2007, 26:32-40.
10. Ding H., Santibanez T.A., Jamieson D.J., Weinbaum C.M., Euler G.L., Grohskopf L.A., et al. Influenza vaccination coverage among pregnant women - National 2009 H1N1 Flu Survey (NHFS). Am J Obstet Gynecol 2011, 204:S96-S106.
11. Omer S.B., Goodman D., Steinhoff M.C., Rochat R., Klugman K.P., Stoll B.J., et al. Maternal influenza immunization and reduced likelihood of prematurity and small for gestational age births: a retrospective cohort study. PLoS Med 2011, 8:e1000441.
12. Rothberg M.B., Haessler S.D., Brown R.B. Complications of viral influenza. Am J Med 2008, 121:258-264.
13. Brydak L.B., Roszkowska-Blaim M., Machala M., Leszczynska B., Sieniawska M. Immunological response to influenza vaccination in children with renal failure. Nephrol Dial Transplant 2001, 16:643-644.
14. Andreeva N.P., Petrova T.I., Golubtsova O.I., Kozhevnikova S.L., Kostinov M.P., Karpocheva S.V., et al. Effect of vaccination against pneumococcal infection and influenza in children with asthma. Zh Mikrobiol Epidemiol Immunobiol 2007, 7:4-7.
15. Centers for Disease Control and Prevention Prevention and control of influenza with vaccines: interim recommendations of the Advisory Committee on Immunization Practices (ACIP), 2013. MMWR Morbidity and mortality weekly report 2013, vol. 62:356.
16. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N., Anderson L.J., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003, 289:179-186.
17. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Bridges C.B., Cox N.J., et al. Influenza-associated hospitalizations in the United States. JAMA 2004, 292:1333-1340.
18. Longini I.M., Halloran M.E. Strategy for distribution of influenza vaccine to high-risk groups and children. Am J Epidemiol 2005, 161:303-306.
19. Whitley R.J., Monto A.S. Prevention and treatment of influenza in high-risk groups: children, pregnant women, immunocompromised hosts, and nursing home residents. J Infect Dis 2006, 194(Suppl. 2):S133-S138.
20. Bhat N., Wright J.G., Broder K.R., Murray E.L., Greenberg M.E., Glover M.J., et al. Influenza-associated deaths among children in the United States, 2003-2004. N Engl J Med 2005, 353:2559-2567.
21. Heikkinen T., Peltola V. Influenza vaccination of children. Lancet Infect Dis 2009, 9:720-721.
22. Belshe R.B., Edwards K.M., Vesikari T., Black S.V., Walker R.E., Hultquist M., et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007, 356:685-696.
23. Rowhani-Rahbar A., Klein N.P., Baxter R. Assessing the safety of influenza vaccination in specific populations: children and the elderly. Expert Rev Vaccines 2012, 11:973-984.
24. Kang E.K., Lim J.S., Lee J.A., Kim D.H. Comparison of immune response by virus infection and vaccination to 2009 pandemic influenza A/H1N1 in children. J Korean Med Sci 2013, 28:274-279.
25. Pabst L.J., Chaves S.S., Weinbaum C. Trends in compliance with two-dose influenza vaccine recommendations among children aged 6 months through 8 years. Vaccine 2013.
26. He X.S., Holmes T.H., Zhang C., Mahmood K., Kemble G.W., Lewis D.B., et al. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol 2006, 80:11756-11766.
27. Lambert L.C., Fauci A.S. Influenza vaccines for the future. N Engl J Med 2010, 363:2036-2044.
28. Monto A.S., Ohmit S.E. Seasonal influenza vaccines: evolutions and future trends. Expert Rev Vaccines 2009, 8:383-389.
29. Koutsonanos D.G., del Pilar Martin M., Zarnitsyn V.G., Jacob J., Prausnitz M.R., Compans R.W., et al. Serological memory and long-term protection to novel H1N1 influenza virus after skin vaccination. J Infect Dis 2011, 204:582-591.
30. Sullivan S.P., Koutsonanos D.G., Del Pilar Martin M., Lee J.W., Zarnitsyn V., Choi S.O., et al. Dissolving polymer microneedle patches for influenza vaccination. Nat Med 2010, 16:915-920.
31. Koutsonanos D.G., Vassilieva E.V., Stavropoulou A., Zarnitsyn V.G., Esser E.S., Taherbhai M.T., et al. Delivery of subunit influenza vaccine to skin with microneedles improves immunogenicity and long-lived protection. Sci Rep 2012, 2:357.
32. Icardi G., Orsi A., Ceravolo A., Ansaldi F. Current evidence on intradermal influenza vaccines administered by Soluvia licensed micro injection system. Hum Vaccines Immunother 2012, 8:67-75.
33. ®) Intradermal vaccine: a promising new chance to increase the acceptability of influenza vaccination in adults. Expert Rev Vaccines 2012, 11:17-25.
34. Koutsonanos D.G., Compans R.W., Skountzou I. Targeting the skin for microneedle delivery of influenza vaccine. Adv Exp Med Biol 2013, 785:121-132.
35. Koutsonanos D.G., del Pilar Martin M., Zarnitsyn V.G., Sullivan S.P., Compans R.W., Prausnitz M.R., et al. Transdermal influenza immunization with vaccine-coated microneedle arrays. PloS ONE 2009, 4:e4773.
36. McElhaney J.E. Influenza vaccine responses in older adults. Ageing Res Rev 2011, 10:379-388.
37. Jepps O.G., Dancik Y., Anissimov Y.G., Roberts M.S. Modeling the human skin barrier - towards a better understanding of dermal absorption. Adv Drug Deliv Rev 2013, 65:152-168.
38. Skountzou I., Quan F.S., Jacob J., Compans R.W., Kang S.M. Transcutaneous immunization with inactivated influenza virus induces protective immune responses. Vaccine 2006, 24:6110-6119.
39. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
40. Steinman R.M. Dendritic cells and the control of immunity: enhancing the efficiency of antigen presentation. Mt Sinai J Med 2001, 68:160-166.
41. Schroder J.M., Reich K., Kabashima K., Liu F.T., Romani N., Metz M., et al. Who is really in control of skin immunity under physiological circumstances - lymphocytes, dendritic cells or keratinocytes. Exp Dermatol 2006, 15:913-929.
42. Lee H.K., Iwasaki A. Innate control of adaptive immunity: dendritic cells and beyond. Semin Immunol 2007, 19:48-55.
43. Itano A.A., McSorley S.J., Reinhardt R.L., Ehst B.D., Ingulli E., Rudensky A.Y., et al. Distinct dendritic cell populations sequentially present antigen to CD4T cells and stimulate different aspects of cell-mediated immunity. Immunity 2003, 19:47-57.
44. Valladeau J., Ravel O., Dezutter-Dambuyant C., Moore K., Kleijmeer M., Liu Y., et al. Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. Immunity 2000, 12:71-81.
45. del Pilar Martin M., Weldon W.C., Zarnitsyn V.G., Koutsonanos D.G., Akbari H., Skountzou I., et al. Local response to microneedle-based influenza immunization in the skin. MBio 2012, 3. e00012-12.
46. Boyden A.W., Frickman A.M., Legge K.L., Waldschmidt T.J. Primary and long-term B-cell responses in the upper airway and lung after influenza A virus infection. Immunol Res 2014.
47. O E., Ko E.J., Kim M.C., Lee Y.T., Song J.M., Kwon Y.M., et al. Distinct B-cell populations contribute to vaccine antigen specific-antibody production in a transgenic mouse model. Immunology 2014.
48. Rothaeusler K., Baumgarth N. B-cell fate decisions following influenza virus infection. Eur J Immunol 2010, 40:366-377.
49. Crotty S. Follicular helper CD4T cells (TFH). Annu Rev Immunol 2011, 29:621-663.
50. Fazilleau N., Mark L., McHeyzer-Williams L.J., McHeyzer-Williams M.G. Follicular helper T cells: lineage and location. Immunity 2009, 30:324-335.
51. Takemori T., Kaji T., Takahashi Y., Shimoda M., Rajewsky K. Generation of memory B cells inside and outside germinal centers. Eur J Immunol 2014, 44:1258-1264.
52. Berzofsky J.A., Ahlers J.D., Belyakov I.M. Strategies for designing and optimizing new generation vaccines. Nat Rev 2001, 1:209-219.
53. Norman J.J., Arya J.M., McClain M.A., Frew P.M., Meltzer M.I., Prausnitz M.R. Microneedle patches: usability and acceptability for self-vaccination against influenza. Vaccine 2014, 32:1856-1862.
54. Van der Vliet D., Pepin S., Lambert M., Fauchoux N., Donazzolo Y., Dupuy M., et al. Similar immunogenicity of the A/H1N1 2009 pandemic influenza strain when used as a monovalent or a trivalent vaccine. Hum Vaccin 2010, 6:823-828.